



Southern Illinois University
School of Medicine
P.O. Box 3926
Springfield, Illinois 62708

March 22, 1984

U.S. Nuclear Regulatory Agency
Region III
Material's Licensing Branch
799 Roosevelt Road
Glen Ellyn, IL 60137

030-15137

Dear Sirs:

This letter is to advise you of a change in the membership of the Radiological Control Committee for the SIU School of Medicine in Springfield, Illinois. Information on the three new Radiological Control Committee members is enclosed.

If you have any questions regarding this change, please contact Randy Maxey, Radiation Safety Officer at (217) 788-3267.

Sincerely,

Lenore Killam

Lenore Killam
Radiation Safety Technician

LK/aj

Enclosure

NRC License #12-18470-01

RECEIVED BY LFMB	
Date	4/12/84
Log	Apr 2
By	CP
Orig. To	RTH
Action Compl.	CP

170.11(a)(9)
FEE EXEMPT

RECEIVED
MAR 28 1984
REGION III

8408220233 840709
NMS LIC30
12-18470-01 PDR

Control No. 76537

MAR 28 1984

RADIOLOGICAL CONTROL COMMITTEE
1983-84

Satu Somani, Ph.D.; Chairman
Peter Borgia, Ph.D.
Carol Donn-Herndon
Stephen Fisk, D.V.M.
Randy Maxey
John Murphy, M.D.
Charles Neal, M.D.
Allen Nickols, Ph.D.
Jill W. Sullivan, M.D.

TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER Charles E. Neal, M.D.		2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE Illinois
3. CERTIFICATION		
SPECIALTY BOARD A	CATEGORY B	MONTH AND YEAR CERTIFIED C
American Board of Radiology	Diagnostic Radiology with Special Competence in Nuclear Radiology	Written Boards - passed October '82 Oral Boards - to be taken June '83

4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES

FIELD OF TRAINING A	LOCATION AND DATE(S) OF TRAINING B	TYPE AND LENGTH OF TRAINING	
		LECTURE/ LABORATORY COURSES (Hours) C	SUPERVISED LABORATORY EXPERIENCE (Hours) D
a. RADIATION PHYSICS AND INSTRUMENTATION	July '79 - June '83 - Southern Illinois University Affiliated Hospitals - (Memorial Medical Center & St. John's Hospital)	160	
b. RADIATION PROTECTION	Same as above	50	
c. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY	Same as above	80	
d. RADIATION BIOLOGY	Same as above	40	
e. RADIOPHARMACEUTICAL CHEMISTRY	Same as above	80	

5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)

ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
Tc-99m	800 mCi	same as above	18 months	generator elution
Tc-99m	20 mCi	same as above	" "	diagnostic
Xe-133	12 mCi	same as above	" "	"
I-131	0.100mCi	same as above	" "	"
I-123	0.200 mCi	same as above	" "	"
Ga-67	10 mCi	same as above	" "	"
In-111	0.500 mCi	same as above	" "	"
TL-201	3 mCi	same as above	" "	"
I-131	150 mCi	same as above	" "	therapy
P-32	5 mCi	same as above	" "	therapy

CR-51	0.200 mCi	Same as above	18 months	diagnostic
I-125	0.010 mCi	same as above	" "	"
Co-57	0.0005 mCi	same as above	" "	"

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS			KEY TO COLUMN C
FULL NAME			PERSONAL PARTICIPATION SHOULD CONSIST OF:
Charles Eugene Neal			1 Supervised examination of patients to determine the suitability for radioisotope diagnosis and/or treatment and recommendation for prescribed dosage.
STREET ADDRESS			2 Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data.
Memorial Medical Center			3 Adequate period of training to enable physician to manage radioactive patients and follow patients through diagnosis and/or course of treatment.
800 N. Rutledge Street			
CITY	STATE	ZIP CODE	
Springfield	IL	62781	

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION	100	
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME	40	
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES	2	
	KIDNEY FUNCTION STUDIES	450	
	IN VITRO STUDIES		
OTHER	I-123 Thyroid uptake & imaging	200	
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING	100	
P-32	EYE TUMOR LOCALIZATION		
Se-75	PANCREAS IMAGING		
Yb-169	CISTERNOGRAPHY		
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES	210	
OTHER			
Tc-99m	BRAIN IMAGING	50	
	CARDIAC IMAGING	40	
	THYROID IMAGING	12	
	SALIVARY GLAND IMAGING	3	
	BLOOD POOL IMAGING	320	
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING	400	
	LUNG IMAGING	250	
	BONE IMAGING	600	
OTHER			

PRECEPTOR STATEMENT (Continued)

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN (Continued)

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES	3	
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
I-131	TREATMENT OF THYROID CARCINOMA	8	
	TREATMENT OF HYPERTHYROIDISM	22	
Au-198	INTRACAVITARY TREATMENT		
Co-60 or Cs-137	INTERSTITIAL TREATMENT		
	INTRACAVITARY TREATMENT		
I-125 or Ir-192	INTERSTITIAL TREATMENT		
Co-60 or Cs-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
	RADIOPHARMACEUTICAL PREPARATION	30	
Mo-99/ Tc-99m	GENERATOR	10	
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS	30	
Other			
Tc-99m	Hepatobiliary imaging	50	
Ga-67	Tumor or inflammatory imaging	15	
TL-201	Myocardial imaging	60	
In-111	Cisternography	12	
Tc-99m	Blood loss	20	
Tc-99m	Testicular imaging	8	
Tc-99m	Renal imaging	25	

3. DATES AND TOTAL NUMBER OF HOURS RECEIVED IN CLINICAL RADIOISOTOPE TRAINING

July 1979 - June 1983 - 1000 hours

Months specifically spent in Nuclear Medicine Training (18 months) are as follows:
Dec. '79, Nov. '80, July '81, Oct. '81, Dec. '81, Feb. '82, July '82 thru June '83

4. THE TRAINING AND EXPERIENCE INDICATED ABOVE WAS OBTAINED UNDER THE SUPERVISION OF:

a. NAME OF SUPERVISOR

Roland D. Cull, M.D.

b. NAME OF INSTITUTION SIU School of Medicine
Affiliated Hospitals

c. MAILING ADDRESS Memorial Medical Center

800 North Rutledge Street

d. CITY

Springfield, IL 62781

5. MATERIALS LICENSE NUMBER(S)

12-00089-02

6. PRECEPTOR'S SIGNATURE

Roland D. Cull M.D.

7. PRECEPTOR'S NAME (Please type or print)

Roland D. Cull, M.D.

8. DATE

4/8/83

Supplement B

Item 4

Licensed material listed in Item 6 is requested to be used by, or under the supervision of, the following individual(s) for the materials and uses indicated:

David B. Lewis, M.D.	Groups I, II, III, IV, V, <u>In Vitro</u> studies, Xenon-133, and Nickel-63
D.W. Sherrick, M.D.	Groups I, II, III, IV, V, <u>In Vitro</u> studies, Xenon-133, and Nickel-63
Charles H. Williams, M.D.	Groups I, II, III, IV, V, <u>In Vitro</u> studies, Xenon-133, and Nickel-63
Roland D. Cull, M.D.	Groups I, II, III, IV, V, <u>In Vitro</u> studies, Xenon-133, and Nickel-63
John G. Dietrich, M.D.	Group I, <u>In Vitro</u> studies, and Nickel-63
Alan J. Stutz, M.D.	Groups II, III, IV, V, VI, <u>In Vitro</u> studies, Xenon-133
Peter McConnachie, Ph.D.	<u>In Vitro</u> studies and Nickel-63
R. Bruce Hoskins, M.D.	Groups IV, V, VI
Parashar J. Nanavati, M.D.	Groups IV, V, VI
Thomas P. Lake, M.D.	Groups I, II, III, IV, V, <u>In Vitro</u> studies Xenon-133, and Nickel-63
David Porter, M.D.	Groups I, II, III, <u>In Vitro</u> studies, Xenon-133 Nickel-63
<u>Charles Neal, M.D.</u>	Groups I, II, III; <u>In Vitro</u> studies; ¹³¹ I for treatment of hyperthyroidism, cardiac dysfunction, and thyroid carcinoma; ³² P as soluble phosphate for treatment of polycythemia vera, leukemia, and bone metastases; ⁶³ Ni; ¹³³ Xe
Steven J. Jackman, M.D.	Groups I, II, III, <u>In Vitro</u> studies, Xenon-133 Nickel-63
John Murphy, M.D.	<u>In Vitro</u> studies and Nickel-63
Nicholas A. Detorie, Ph.D.	Sealed sources, containing 60 mCi or less in each sealed source, for calibration or reference.
Randy B. Maxey, M.S.	Sealed sources, containing 60 mCi or less in each sealed source, for calibration or reference
John T. Stalp, M.S.	Sealed sources, containing 60 mCi or less in each sealed source, for calibration or reference